Company research
UroGen Pharma Ltd.
CIK 1668243Updated Nov 14, 2026
SecurityURGN · NASDAQ · equity
URGN price & chart
Loading TradingView…
NASDAQ:URGN on TradingView ↗In the news
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm News provided by The Schall Law Firm Jun 16, 2025, 10:38 ET Share this article Share to X Share this article Share to X LOS ANGELES , June 16, 2025 /PRNewswire/ -- The Schall Law Firm , a nat ↗
UroGen Pharma Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 28, 2025 to Discuss Your Rights - URGN News provided by Levi & Korsinsky, LLP Jun 13, 2025, 05:45 ET Share this article Share to X Share this article Share to X NEW YORK , June 13, 2025 /PRNewswire/ -- Levi ↗
Seeking Alpha
UroGen: Opportunity Builds As Rough Patch Gets Brutal ↗
UroGen expects profitability and positive cash flow in Q4 2026 as ZUSDURI grows 35% sequentially ↗
UroGen Pharma Ltd. (URGN) Q3 2026 Earnings Call Transcript ↗
SEC disclosures
UroGen Pharma Ltd. files 8-K: Material Event ↗
Recent filings
SCHEDULE 13G/A - filed by TORONTO DOMINION BANK regarding UroGen Pharma Ltd.
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
144 filing
Show 5 more recent filings
4 filing
Other Events
Items 8.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 185,046,000Source | 301,943,000Source | 252,590,000Source | 208,717,000Source | 281,849,000Source | 253,690,000Source | 247,618,000Source | 200,574,000Source | 200,455,000Source | 285,711,000Source | 178,311,000Source | 135,619,000Source |
| Property, Plant and Equipment, NetUSD | 695,000Source | 608,000Source | 597,000Source | 688,000Source | 580,000Source | 616,000Source | 627,000Source | 566,000Source | 637,000Source | 655,000Source | 689,000Source | 1,297,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 90,039,000Source | 124,916,000Source | 79,133,000Source | 92,904,000Source | 219,972,000Source | 109,968,000Source | 104,033,000Source | 131,439,000Source | 110,745,000Source | 171,987,000Source | 95,002,000Source | 55,408,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 19,703,000Source | 22,802,000Source | 88,757,000Source | 19,649,000Source | 17,415,000Source | 55,412,000Source | 19,638,000Source | 14,158,000Source | 33,082,000Source | 20,302,000Source | 15,443,000Source | 12,704,000Source |
| Inventory, NetUSD | 8,341,000Source | 7,594,000Source | 24,589,000Source | 7,128,000Source | 7,442,000Source | 20,921,000Source | 7,590,000Source | 7,243,000Source | 16,464,000Source | 9,227,000Source | 5,673,000Source | 4,325,000Source |
| Assets, CurrentUSD | 168,546,000Source | 295,097,000Source | 235,426,000Source | 196,868,000Source | 278,968,000Source | 237,464,000Source | 237,177,000Source | 196,760,000Source | 186,024,000Source | 276,135,000Source | 169,186,000Source | 128,907,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 12,122,000Source | 14,053,000Source | 12,776,000Source | 12,055,000Source | 12,208,000Source | 19,530,000Source | 12,983,000Source | 10,491,000Source | 14,672,000Source | 8,845,000Source | 10,281,000Source | 11,101,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,098,000Source | 1,052,000Source | 2,810,000Source | 1,210,000Source | 1,250,000Source | 2,931,000Source | 641,000Source | 1,443,000Source | 3,080,000Source | 849,000Source | 1,671,000Source | 2,452,000Source |
| Other Assets, NoncurrentUSD | 6,759,000Source | 370,000Source | 8,761,000Source | 801,000Source | 673,000Source | 7,493,000Source | 371,000Source | 1,098,000Source | 5,161,000Source | 589,000Source | 2,038,000Source | 2,740,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 300,454,000Source | 276,428,000Source | 384,986,000Source | 302,093,000Source | 251,535,000Source | 377,943,000Source | 294,076,000Source | 240,708,000Source | 305,929,000Source | 294,514,000Source | 243,523,000Source | 224,980,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 128,000Source | 115,000Source | 135,000Source | 126,000Source | 112,000Source | 134,000Source | 126,000Source | 99,000Source | 133,000Source | 115,000Source | 89,000Source | 63,000Source |
| Retained Earnings (Accumulated Deficit)USD | -933,352,000Source | -768,710,000Source | -997,641,000Source | -900,005,000Source | -745,037,000Source | -983,290,000Source | -850,065,000Source | -711,634,000Source | -959,716,000Source | -806,222,000Source | -679,348,000Source | -577,104,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 23,000Source | 236,000Source | -2,000Source | 6,000Source | -31,000Source | 8,000Source | 14,000Source | -37,000Source | 19,000Source | 56,000Source | 12,000Source | -107,000Source |
| Stockholders' Equity Attributable to ParentUSD | -115,408,000Source | 25,515,000Source | -132,396,000Source | -93,376,000Source | 30,314,000Source | -124,253,000Source | -46,458,000Source | -40,134,000Source | -105,474,000Source | -8,803,000Source | -65,212,000Source | -89,361,000Source |
| Additional Paid in Capital, Common StockUSD | 817,793,000Source | 793,874,000Source | 865,112,000Source | 806,497,000Source | 775,270,000Source | 858,895,000Source | 803,467,000Source | 671,438,000Source | 854,090,000Source | 797,248,000Source | 614,035,000Source | 487,787,000Source |
| Liabilities and EquityUSD | 185,046,000Source | 301,943,000Source | 252,590,000Source | 208,717,000Source | 281,849,000Source | 253,690,000Source | 247,618,000Source | 200,574,000Source | 200,455,000Source | 285,711,000Source | 178,311,000Source | 135,619,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 42,244,000Source | 32,787,000Source | 61,915,000Source | 47,548,000Source | 34,223,000Source | 50,635,000Source | 42,000,000Source | 26,340,000Source | 46,418,000Source | 45,949,000Source | 31,212,000Source | 23,916,000Source |
| Operating Lease, Liability, CurrentUSD | 429,000Source | 825,000Source | 684,000Source | 668,000Source | 796,000Source | 589,000Source | 634,000Source | 779,000Source | 481,000Source | 785,000Source | — | — |
| Accounts Payable, CurrentUSD | 10,279,000Source | 5,556,000Source | 15,472,000Source | 13,564,000Source | 8,317,000Source | 17,209,000Source | 14,567,000Source | 6,259,000Source | 12,137,000Source | 10,931,000Source | 6,514,000Source | 5,527,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,674,000Source | 212,000Source | 2,360,000Source | 552,000Source | 425,000Source | 2,485,000Source | 3,000Source | 637,000Source | 2,646,000Source | 58,000Source | 844,000Source | 1,586,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 127,400,000Source | 254,200,000Source | 108,000,000Source | 161,600,000Source | 241,300,000Source | 140,300,000Source | 200,400,000Source | 164,500,000Source | 120,500,000Source | 241,700,000Source | 141,500,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 122,111,000Source | 121,709,000Source | 188,734,000Source | 122,508,000Source | 97,813,000Source | 189,530,000Source | 122,108,000Source | 97,590,000Source | 122,210,000Source | 121,734,000Source | 98,551,000Source | 97,537,000Source |
| Short-term InvestmentsUSD | 63,790,000Source | 153,934,000Source | 30,162,000Source | 83,111,000Source | 52,282,000Source | 39,741,000Source | 112,030,000Source | 51,721,000Source | 49,310,000Source | 110,672,000Source | 56,160,000Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 75,000Source | 72,000Source | 307,000Source | 329,000Source | 802,000Source | 924,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 4,627,000Source | 3,069,000Source | 11,959,000Source | 13,108,000Source | 9,343,000Source | 10,580,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 22,330,000Source | -664,000Source | 12,780,000Source | 4,859,000Source | 2,739,000Source | 987,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 4,457,000Source | -1,637,000Source | 7,237,000Source | 3,554,000Source | 1,348,000Source | 362,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -45,316,000Source | -42,024,000Source | -162,444,000Source | -96,766,000Source | -76,376,000Source | -87,559,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -20,688,000Source | -25,963,000Source | 61,558,000Source | -20,613,000Source | -953,000Source | 1,060,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 54,000Source | 44,000Source | 289,000Source | 295,000Source | 194,000Source | 254,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 65,204,000Source | 34,000Source | 39,918,000Source | 194,619,000Source | 116,931,000Source | 97,134,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -800,000Source | -67,953,000Source | -60,968,000Source | 77,240,000Source | 39,602,000Source | 10,635,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 3,000,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,027,000Source | 3,489,000Source | 5,331,000Source | 2,733,000Source | 4,627,000Source | 3,069,000Source | 11,959,000Source | 13,108,000Source | 9,343,000Source | 10,580,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 127,400,000Source | 254,200,000Source | 108,000,000Source | 161,600,000Source | 140,300,000Source | 200,400,000Source | 120,500,000Source | 241,700,000Source | 141,500,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | -1,054,000Source | 91,000Source | 5,629,000Source | 1,015,000Source | -4,772,000Source | 392,000Source | 78,000Source | 2,832,000Source | 3,920,000Source | 1,755,000Source |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 870,000Source |
| Investment Income, InterestUSD | — | — | 1,176,000Source | 2,757,000Source | 946,000Source | 1,677,000Source | 931,000Source | 2,204,000Source | 5,965,000Source | 8,901,000Source | 2,641,000Source | 938,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -33,347,000Source | -23,673,000Source | -14,351,000Source | -49,940,000Source | -23,574,000Source | -43,843,000Source | -153,494,000Source | -126,874,000Source | -102,244,000Source | -109,783,000Source |
| Nonoperating Income (Expense)USD | — | — | -197,000Source | -158,000Source | -347,000Source | -378,000Source | -323,000Source | -90,000Source | -670,000Source | -229,000Source | 838,000Source | 72,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 0Source | 4,000Source | 39,801,000Source | 151,169,000Source | 67,358,000Source | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | 65,346,000Source | 0Source | 0Source | 24,488,000Source | 0Source | 95,783,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 4,146,000Source | 40,432,000Source | 139,247,000Source | 107,705,000Source | 49,073,000Source | 64,323,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 179,000Source | 30,000Source | 1,972,000Source | 321,000Source | 873,000Source | 1,511,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 27,482,000Source | 25,204,000Source | 72,456,000Source | 24,215,000Source | 50,959,000Source | 20,254,000Source | 109,788,000Source | 90,398,000Source | 82,713,000Source | 64,357,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Selling, General and Administrative ExpenseUSD | — | — | 37,582,000Source | 28,941,000Source | 48,437,000Source | 43,199,000Source | 51,486,000Source | 34,967,000Source | 155,097,000Source | 121,154,000Source | 93,274,000Source | 82,838,000Source |
| Operating Income (Loss)USD | — | — | -27,386,000Source | -17,545,000Source | 111,000Source | -41,448,000Source | -20,263,000Source | -36,914,000Source | -124,863,000Source | -96,782,000Source | -65,536,000Source | -79,041,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -34,401,000Source | -23,582,000Source | -8,722,000Source | -48,925,000Source | -28,346,000Source | -43,451,000Source | -153,416,000Source | -124,042,000Source | -98,324,000Source | -108,028,000Source |
| Income Tax Expense (Benefit)USD | — | — | -1,054,000Source | 91,000Source | 5,629,000Source | 1,015,000Source | -4,772,000Source | 392,000Source | 78,000Source | 2,832,000Source | 3,920,000Source | 1,755,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -33,347,000Source | -23,673,000Source | -14,351,000Source | -49,940,000Source | -23,574,000Source | -43,843,000Source | -153,494,000Source | -126,874,000Source | -102,244,000Source | -109,783,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.69Source | -0.51Source | -0.28Source | -1.05Source | -0.47Source | -0.92Source | -3.19Source | -2.96Source | -3.55Source | -4.81Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 48,057,386Source | 46,779,637Source | 50,380,112Source | 47,739,816Source | 50,182,758Source | 47,422,119Source | 48,116,098Source | 42,876,737Source | 28,834,303Source | 22,806,812Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 78,000Source | 2,832,000Source | 3,920,000Source | 1,755,000Source |
| Gross ProfitUSD | — | — | 24,204,000Source | 22,751,000Source | 65,884,000Source | 20,665,000Source | 46,820,000Source | 17,924,000Source | 97,341,000Source | 81,517,000Source | 73,352,000Source | 56,703,000Source |
| Interest and Other IncomeUSD | — | — | 979,000Source | 2,599,000Source | 599,000Source | 1,299,000Source | 608,000Source | 2,114,000Source | 5,295,000Source | 8,672,000Source | 3,479,000Source | 1,010,000Source |
| Investment Income, InterestUSD | — | — | 1,176,000Source | 2,757,000Source | 946,000Source | 1,677,000Source | 931,000Source | 2,204,000Source | 5,965,000Source | 8,901,000Source | 2,641,000Source | 938,000Source |
| Nonoperating Income (Expense)USD | — | — | -197,000Source | -158,000Source | -347,000Source | -378,000Source | -323,000Source | -90,000Source | -670,000Source | -229,000Source | 838,000Source | 72,000Source |
| Research and Development ExpenseUSD | — | — | 14,008,000Source | 11,355,000Source | 17,336,000Source | 18,914,000Source | 15,597,000Source | 19,871,000Source | 67,107,000Source | 57,145,000Source | 45,614,000Source | 52,906,000Source |
Filing attachments
d903812dex991.htm · 8-K · 2025-01-14
EX-99.1 2 d903812dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Developing Innovative Medicines to Treat Urothelial Cancers January 2025 Disclaimers This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential of UroGen’s proprietary technology to enhance proven and novel medicines and deliver them aligned with the way urologists practice; the estimated addressable patie…
Read attachment ↗